Tyrosine kinase inhibitor (TKI)-induced thyroid hormone abnormalities result from interference with the #HPT axis and peripheral #thyroid #hormone metabolism regulators thelancet.com/journals/lan...
#hypothyroidism #TKIs

#MedSky #EndoSky #OncSky

Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer What are the key receptor tyrosine kinases involved in the pathogenesis and progression of thyroid cancer? And what role can tyrosine kinase inhibitors play in the management of advanced disease?

What are the key receptor tyrosine kinases involved in the pathogenesis and progression of #ThyroidCancer?

And what role can #TKIs play in the management of advanced disease?

Find out in this review 👉 buff.ly/ejchq7I

#OncSky

We reflect on a key breakthrough in the treatment of #CML with Dr. Jorge Cortes, who has been involved in the development of #TKIs since the early days.

👉 buff.ly/nqiq2ZY

#CancerTreatments

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism Tyrosine kinase inhibitors (TKIs) are anti-cancer agents that inhibit the activity of oncogenic protein kinases. Thyroid hormone abnormalities are common during treatment with TKIs, typically manifest...

The combined action of #TKIs on #thyroid gland function & peripheral deiodinases generates a unique phenotype of primary #hypothyroidism characterised by increased TSH concentrations & a reduced T3 to T4 ratio www.thelancet.com/journals/lan...
#tyrosine #kinase #inhibitors #thyroidcancer
#EndoSky

#Olverembatinib, a novel #MultiKinaseInhibitor, demonstrates strong efficacy and safety in SDH-deficient GISTs resistant to #TKIs, mechanistically suppressing #LipidUptake and #CD36-associated tumorigenic pathways. #GISTs #CD36

#OpenAccess in #STTT: doi.org/10.1038/s413...

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism Tyrosine kinase inhibitors (TKIs) are anti-cancer agents that inhibit the activity of oncogenic protein kinases. Thyroid hormone abnormalities are common during treatment with TKIs, typically manifest...

The combined action of tyrosine kinase inhibitors (TKIs) on #thyroid gland function & peripheral deiodinases generates a unique phenotype of primary #hypothyroidism characterised by increased TSH concentrations & a reduced T3 to T4 ratio www.thelancet.com/journals/lan...
#TKIs

#EndoSky #OncSky

Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer - OncoDaily Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer / Alfredo Addeo, CA: A Cancer Journal for Clinicians, cancer, Claudio De Vito, Giuseppe

A True Game Changer in Targeted Therapy for Lung Cancer - Alfredo Addeo
@alfdoc2.bsky.social
@jillfeldman4.bsky.social

oncodaily.com/science/targ...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TargetedTherapy #LungCancer #TKIs

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism Tyrosine kinase inhibitors (TKIs) are anti-cancer agents that inhibit the activity of oncogenic protein kinases. Thyroid hormone abnormalities are common during treatment with TKIs, typically manifest...

New Review:
The unique signature of tyrosine kinase inhibitor-induced #hypothyroidism thelancet.com/journals/lan...
#TKIs #thyroid

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell lines

➡️ buff.ly/iMUNTQC

@MartMichaelis @markwassy @MichelleDGarre2 @CampbellGourlay

#EGFR #TKIs #NSCLC

Yan Leyfman: Final results are in from a Phase 1 trial combining asciminib with ATP-competitive TKIs in CML - OncoDaily Yan Leyfman: Final results are in from a Phase 1 trial combining asciminib with ATP-competitive TKIs in CML / Andreas Hochhaus, cancer, Daniel J. DeAngelo,

Final results are in from a Phase 1 trial combining asciminib with ATP-competitive TKIs in CML - Yan Leyfman
@yleyfman.bsky.social

oncodaily.com/insight/yan-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CML #TKIs

Osimertinib Monotherapy (The FLAURA clinical trial):

Both progression-free and overall survival were longer with Osimertinib than with first-generation EGFR TKIs.

@JuliaRotow
#LungCancer #Osimertinib #EGFR #TKIs #TheFlauraClinicalTrial